Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Kasper

Internal Medicine East Haven, CT Medical Doctor

NPI 1780648238 CMS profile 262759

339 Hemingway Ave, East Haven, CT 06512

Open in the dashboard

General payments

$3,595

187 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Kasper of East Haven, CT is reported in the CMS Open Payments database as having received $3,595 across 187 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $820 35
2024 General $862 53
2023 General $652 31
2022 General $445 21
2021 General $325 17
2020 General $205 13
2019 General $286 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Kasper
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Mark Kasper were reported at $820. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Mark Kasper Internal Medicine median Middle half National median
2019 $286 $159 $48–$570 $163
2020 $205 $119 $33–$402 $114
2021 $325 $135 $37–$521 $132
2022 $445 $141 $42–$496 $149
2023 $652 $149 $45–$519 $160
2024 $862 $154 $47–$537 $164
2025 $820 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $685 37 payments
  2. AstraZeneca Pharmaceuticals LP $481 23 payments
  3. AbbVie, Inc. $409 20 payments
  4. Lilly USA, LLC $409 21 payments
  5. Novo Nordisk Inc $329 21 payments
  6. Pfizer Inc. $162 8 payments
  7. Exact Sciences Corporation $126 6 payments
  8. Merck Sharp & Dohme Corporation $115 6 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $101 5 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $87 4 payments
  11. Other $691 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,595 187 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $625 34 payments
  2. BREZTRI $270 13 payments
  3. MOUNJARO $206 10 payments
  4. AIRSUPRA $198 9 payments
  5. JARDIANCE $190 10 payments
  6. Ozempic $178 15 payments
  7. RYBELSUS $178 15 payments
  8. VRAYLAR $163 8 payments
  9. UBRELVY $161 8 payments
  10. Wegovy $127 5 payments
  11. Other $2,194 114 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 116 drugs

Part D claims

9,183

Median for Internal Medicine: 777

Drug cost

$536,713

Median for Internal Medicine: $73,373

Branded share of claims

14.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 91 $109,731
Ozempic Semaglutide Brand 71 $78,530
Jardiance Empagliflozin Brand 55 $75,903
Januvia Sitagliptin Phosphate Brand 43 $64,952
Eliquis Apixaban Brand 51 $44,169
Farxiga Dapagliflozin Propanediol Brand 29 $26,856
Myrbetriq Mirabegron Brand 15 $18,233
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 17 $12,472
Atorvastatin Calcium Generic 1,061 $7,893
Lagevrio (Eua) Molnupiravir Brand 13 $5,817

The 10 drugs with the highest cost, of 116 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$248,970

Of which drugs: $32,511

Medicare patients

358

Average age 77

Services billed

4,825

178 women, 180 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 47%
Chronic kidney disease 30%
Ischemic heart disease 29%
Diabetes 25%
Heart failure 19%
Atrial fibrillation 19%
Cancer 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 176 179 $14,563
Sarscv2 vac 30mcg trs-suc im 91320 Office 64 66 $9,986
Sarscov2 vac 50 mcg/0.5ml im 91322 Office 37 39 $6,132

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $172
$172 17 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $107
$107 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $74
$74 — —
MOUNJARO
  • Lilly USA, LLC $73
$73 91 —
RYBELSUS
  • Novo Nordisk Inc $57
$57 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

187 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record